An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia
RO7283420, developed by Hoffmann-La Roche, is currently in Phase 1 clinical trials targeting hematologic and molecular relapsed/refractory Acute Myeloid Leukemia (AML). The asset aims to address a significant unmet need in a market characterized by limited treatment options for patients who have exhausted standard-of-care therapies. The competitive landscape includes existing therapies such as targeted agents and immunotherapies, but RO7283420's unique mechanism as a bispecific antibody targeting WT1 may provide a differentiated therapeutic profile. Successful outcomes in this trial could position Roche favorably for subsequent Phase 2 studies and potential market entry, enhancing its portfolio in oncology and solidifying its presence in the AML treatment space.
Indication: Acute Myeloid Leukemia
Modality: small molecule
Target: HLA-A*02
Sponsor: Hoffmann-La Roche
Source URL: ClinicalTrials.gov
Source updated: Jun 03, 2024
Ingested: Jun 16, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: HLA-A*02
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: HLA-A*02
Target normalized: HLA-A*02